Menu
Menu
Tirzepatide works on two metabolic pathways at once. In head-to-head trials it outperformed semaglutide on weight loss. Prescribed after a physician exam and full labs, then managed with monthly in-person visits and body composition scanning at our Palm Harbor clinic.
Tirzepatide activates two gut hormone receptors instead of one. GLP-1 reduces appetite and slows gastric emptying. GIP (glucose-dependent insulinotropic polypeptide) improves how your body handles fat and glucose, and appears to enhance the weight-loss effect of GLP-1 through a complementary mechanism. The combination produces larger average weight loss than semaglutide in clinical trials, particularly at higher BMI and in patients with significant insulin resistance.
We prescribe a compounded version prepared by a licensed US compounding pharmacy. Same active molecule as Mounjaro (type 2 diabetes) and Zepbound (weight loss), both made by Eli Lilly. Dosing matches the published SURMOUNT trial titration schedule.
If you’re new to GLP-1 therapy entirely, it may be worth reading our compounded semaglutide page first, since that’s usually the starting point. If you’ve already been on semaglutide and plateaued, tirzepatide is often the logical next move.
This is not a telehealth questionnaire. It’s a real medical program.
A full review of your goals, weight history, current medications, and any relevant family history. We decide together whether tirzepatide is the right fit for you specifically.
Baseline A1c, thyroid, kidney, liver, and lipid panel, plus an InBody body composition scan that separates fat mass from skeletal muscle. Your physician writes a dosing and titration plan off those numbers, not off a template.
An in-person visit every four weeks: exam, weight, repeat InBody scan, and labs rechecked on schedule. Dose adjustments are made on what your body is actually doing, not on a default titration calendar.
Semaglutide is usually the first-line choice and the more studied of the two. Tirzepatide tends to be the better pick when you have a higher BMI (over 35), significant insulin resistance, a history of PCOS with metabolic features, or haven’t hit your goal on semaglutide alone.
In the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022), patients on the 15 mg tirzepatide dose lost 22.5% of their body weight over 72 weeks. For context, the best semaglutide result in a comparable trial was 14.9%. SURMOUNT-5, published in 2025, was a head-to-head comparison that confirmed a significant advantage for tirzepatide on weight outcomes. Your provider will help you weigh the decision against cost, tolerance, and your specific goals.
We often start patients on semaglutide, optimize for 4 to 6 months, and switch to tirzepatide only if progress plateaus. That sequencing tends to be kinder on the GI side effects and saves money for patients whose bodies respond well to the single-agonist.
Tirzepatide’s weight-loss evidence comes from the SURMOUNT trial program. SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity and followed them for 72 weeks. Mean weight loss was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses. The proportion of patients losing 20% or more of their body weight was 30% on the 5 mg dose and 57% on the 15 mg dose.
SURMOUNT-3 looked at patients who first completed a 12-week intensive lifestyle intervention before starting tirzepatide. Those patients achieved 21.1% additional weight loss on top of their initial progress, confirming that medication and lifestyle work synergistically rather than competitively.
SURMOUNT-5 (2025) was the first direct head-to-head against semaglutide. At the highest doses of each, tirzepatide produced meaningfully greater weight loss with a similar safety profile, which cemented it as a reasonable first-line choice for patients who can tolerate the full titration.
Week 1–4. Starting dose is 2.5 mg weekly for the first four weeks. This is the tolerance-building phase. Expect reduced appetite within days and mild GI side effects that improve week over week. We check in at week two.
Week 5–8. Dose advances to 5 mg. Appetite suppression deepens. Most patients begin seeing 2–5 lbs per week of weight loss and start noticing clothes fit differently. Hydration and protein targets become critical.
Week 9–12. Dose moves to 7.5 mg if tolerated. This is typically the dose where patients settle for the first maintenance stretch. We repeat a brief lab panel and assess body composition changes to confirm you’re losing fat, not muscle.
From month four onward, most patients stabilize between 7.5 and 12.5 mg depending on goals and tolerance. A subset reach 15 mg if their target requires it. We revisit dose every month and don’t push harder than your body is ready for.
Anyone can put tirzepatide in a box and ship it. This is what the monthly visit is actually for.
Vitals, blood pressure, and an abdominal and thyroid exam with Oliver Morris, DO. Nausea you should expect and gallbladder pain you should not look almost identical through a chat window. In the room, they do not.
The bathroom scale cannot tell fat from muscle. InBody can. Sixty seconds on the device splits your weight into fat mass, skeletal muscle mass, and body water, so we know the pounds coming off are the pounds you wanted off.
A1c, kidney, liver, thyroid, and lipids before your first dose, repeated on schedule. Undiagnosed thyroid disease, fatty liver, and early kidney strain surface here first. None of them surface on a questionnaire.
Subscription programs step your dose up on a shipping schedule. We hold, slow, split, or advance based on your labs, your scan, and how the last four weeks actually went.
Protein targets set against your goal weight, resistance training guidance, and monthly proof from your scan. Fast loss without this quietly costs you lean mass you will want back.
Most people regain when tirzepatide stops without one. We write the exit plan at your first visit rather than improvising it at month nine.
The same doctor writes every prescription and sees you at every visit. No rotating prescriber pool, no per-message fees, no support queue.
Rapid loss changes skin and facial volume. Low testosterone and obesity travel together in men over 35. Nutrition, peptides, TRT, and aesthetics are all under the same roof here.
Some people should not be on a GLP-1, and some should be worked up for something else first. An online form will sell to every one of them. We turn people away at the consult, and we tell you why.
We are not going to tell you tirzepatide is hard to get. It is easy to get. What is hard to get is someone paying attention while you are on it.
Both routes can put tirzepatide in your hand. Only one of them is watching what it does to you.
Tirzepatide used to be a thousand-dollar-a-month drug at the pharmacy counter. It is not anymore. Eli Lilly now sells Zepbound vials directly to self-pay patients at a fraction of that, and the rest of the market has moved with it. We are not going to build a pitch on savings that no longer exist.
So here is the straight version. If the lowest possible price on the molecule is your only variable, buying direct from the manufacturer is a legitimate option, and we will tell you so at your consult instead of talking you out of it. What we charge for is not a discount on a drug. It is the medicine around the drug: the physical exam, the baseline and follow-up labs, the monthly InBody scan, dose decisions made on your data instead of an autoship calendar, and a physician who answers when something goes wrong.
We are also not locked into compounded medication. If a brand product is the better fit for your dose, your coverage, or your tolerance, we will write it and manage you on it. The care is identical either way. Program pricing depends on your dose and program length, and covers the medication, supplies, your monthly in-person visit, and your body composition scans. Labs are billed separately at wholesale. HSA, FSA, and CareCredit are supported, and we quote exact numbers at your consultation.
On weight loss alone, head-to-head trials favor tirzepatide at the higher doses. It’s not automatically the right choice for everyone, though. Cost, side-effect profile, and how your body handles dual-receptor therapy all matter. We’ll walk through the trade-offs at your visit.
The active molecule is the same. Mounjaro (type 2 diabetes) and Zepbound (weight loss) are Eli Lilly brand versions; ours is prepared by a licensed US 503A compounding pharmacy. Lilly has cut its self-pay vial pricing substantially, so the two are far closer on cost than they were. We prescribe both and will compare them honestly at your dose before you decide.
GI side effects lead the list: nausea, reflux, constipation, occasional diarrhea. They’re almost always dose-related and improve with slower titration. Less commonly: gallbladder issues, pancreatitis, and thyroid concerns, which is why we run labs and follow up regularly.
Appetite typically drops in the first two weeks. Visible weight loss usually starts around week four and accelerates as the dose climbs. Expect the biggest changes between month three and month nine.
Yes, and it’s a common path. We review your current labs and dose, then start tirzepatide at a titration that fits where you are. Most patients cross over without a washout period.
Compounded GLP-1/GIP medications are self-pay, and brand coverage for weight loss remains inconsistent. Eli Lilly now sells Zepbound vials direct to cash patients, which changed the math for a lot of people, so we walk through both routes with real numbers at your visit rather than assuming ours wins. HSA and FSA funds are usually eligible either way.
Like any rapid weight loss, a portion of the loss can be lean mass, and tirzepatide moves weight fast. We counter it with a protein target set against your goal weight (0.8 to 1.0 g per pound), resistance training two to three times per week, and an InBody scan at every monthly visit. That scan is the point: it separates fat mass from skeletal muscle, so we catch muscle loss in the month it starts rather than at the end.
Moderate alcohol is fine for most patients. Delayed gastric emptying can intensify the effect of alcohol, so expect to feel it faster and longer. We recommend dialing back initially and seeing how you respond.
Without a taper and a maintenance plan, most patients regain significant weight within six to twelve months. We build the exit plan at the start: a slow taper, a maintenance dose for many, and intentional lifestyle anchors.
Oliver Morris, DO is the prescribing physician at Olympia Aesthetics & Wellness. You see him at every visit. Learn more on the Oliver Morris, DO bio page.
Fair question, and the price drop is real. What a manufacturer or a website sells you is the drug. What we sell is the drug plus the medicine around it: a physical exam, labs that get repeated, a monthly body composition scan so we can prove you are losing fat rather than muscle, dose decisions made on your data, and a physician who picks up the phone when something goes wrong. If you would rather have the vial and manage the rest yourself, that is a reasonable choice and we will say so. We just will not pretend the two are the same thing.
Yes. We are not locked into compounded medication. If the brand product is the better fit for your dose, your coverage, or your tolerance, we will write it and manage you on it. The exam, labs, scans, and follow-up are identical either way.
InBody is a body composition analyzer. You stand on it for about a minute and it separates your weight into fat mass, skeletal muscle mass, and body water. It matters more on tirzepatide than on almost anything else, because the weight comes off fast and a meaningful share of it can be muscle if nobody is measuring. The monthly scan is what tells us whether to advance your dose, hold it, or fix your protein and training first.
Yes, and on a dual-agonist it matters more, not less. Tirzepatide titrates across a wide dose range and moves weight quickly, so the monthly exam, scan, and lab checkpoints are what keep the pace safe. Patients who skip in-person follow-up are the ones who plateau on the wrong dose, lose lean mass without knowing it, or sit on a side effect that should have been managed weeks earlier. Visits run about 20 minutes.
Tirzepatide is a real medication with a specific risk profile. We decline to prescribe when any of the following apply, and we will say so at your consult rather than waste your time.
Individual response varies. This is the pattern most of our patients follow over the first six months.
Lowest dose to assess tolerance. Mild nausea and reduced appetite are common. Hydration and protein-forward meals help early-dose side effects.
First monthly check-in. If you are tolerating 2.5 mg well, we step up to 5 mg. Most patients are 3 to 5% down from starting weight.
Second step. Body composition shifts visible to patient and provider. Labs on schedule check glucose, lipids, and CBC.
Middle of the dose-response curve. HbA1c often improves materially here. We assess whether further titration makes sense.
Many patients settle between 10 and 15 mg. Steady state where side effects are minimal and appetite regulation feels routine. Taper planning begins.
We quote at consultation because the right dose, duration, and bundle depend on your goals and labs. Here is the context.
The medication, prepared by a licensed US compounding pharmacy and shipped to you monthly, or a brand product if that is the better fit. An in-person physician exam with Oliver Morris, DO. Monthly in-person follow-up with the same physician. Baseline and follow-up labs at scheduled checkpoints. An InBody body composition scan at every visit. Titration, side-effect management, muscle-preservation and nutrition guidance, and a taper plan, all included.
What you are not paying for: membership fees, per-message charges, rotating prescriber pools, or hidden escalations.
Brand self-pay pricing has dropped sharply. Eli Lilly sells Zepbound vials direct to cash patients now, and Novo Nordisk does the same for Wegovy, so the old thousand-dollar comparison is dead and we are not going to quote it. We do not claim to beat the manufacturer on the molecule alone. What we compete on is the care: a physician exam, labs, a monthly InBody scan, and a dose decided by your data. Telehealth compounding programs are priced near us but sell a questionnaire and a shipment. Ours is a different product from either.
We quote the full 6 to 12 month program at consultation so you have the total, not a teaser price, and we will show you what the brand route would cost you at your dose so you can compare the two honestly.
Book an in-person consultation in Palm Harbor. We’ll review your history, run baseline labs, and build a plan the same day.
Contact information is for the sole use of
Olympia Aesthetics & Wellness and will not be redistributed.
Olympia Aesthetics & Wellness
33295 US Hwy 19 N #109
Palm Harbor, FL 34684
(727) 274-1972
Get directions
10 am – 6 pm Monday
10 am – 6 pm Tuesday
10 am – 6 pm Wednesday
10 am – 6 pm Thursday
10 am – 6 pm Friday
10 am – 2 pm Saturday
10 am – 2 pm Sunday
Accessibility: Olympia Aesthetics & Wellness is committed to ensuring our website is accessible to all users. If you experience any difficulty, please contact us at (727) 274 – 1972 or olympia@olympiaaesthetics.com. Click for more details